AstraZeneca released its FY24 financials, showing strong growth across its portfolio. Here's a quick breakdown of its performance.

How much did pharma spend on sales in marketing in 2024?

SG&A (Selling, General, and Administrative) expenses in pharma cover the costs of running the business

These include marketing, sales, HR, legal fees, compliance costs, etc.

SG&A usually takes somewhere between 25-30% of the revenue

GSK released its financial statements showing steady growth in revenue but significant cost increases impacting profitability.

Here is a breakdown of how the company performed in FY24

Here’s a quick breakdown of how Pfizer performed in FY24

⚆ Pfizer reported $63.9 billion in revenue (7% Y/Y growth).

⚆ Comirnaty still generated over $3.36 billion in sales.

⚆ Pfizer allocated $10.8 billion to R&D - this is 16.9% of their revenue.

These 13 big pharma companies have generated a total revenue of almost 700 billion USD!

The financial reporting season is ongoing, and most pharma companies have now released their unaudited reports.

The pharma sector has shown year-on-year revenue growth, and 2024 is no exception.

Eli Lilly and Company is another diabetes/obesity giant that released its financials from 2024 (unaudited).

Here’s a quick breakdown of how the company performed in FY24.

AbbVie reported their financial performance on January 31st. Here is the recap from their interim financial report.

𝐆𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐟𝐨𝐫 𝐬𝐢𝐜𝐤𝐥𝐞 𝐜𝐞𝐥𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐚𝐫𝐞 𝐟𝐢𝐧𝐚𝐥𝐥𝐲 𝐫𝐞𝐚𝐜𝐡𝐢𝐧𝐠 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬

In 2023, two gene therapies were approved for SCD, but only a few patients have accessed them so far.

These therapies are finally reaching patients.

𝐖𝐡𝐚𝐭 𝐜𝐞𝐥𝐥 𝐚𝐧𝐝 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐚𝐫𝐞 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐔𝐒 𝐚𝐧𝐝 𝐄𝐮𝐫𝐨𝐩𝐞?

2024 is over. This has been a good year for cell and gene therapies, especially in the US market, where 9 new CGT products* were approved.

𝐇𝐨𝐰 𝐰𝐢𝐥𝐥 𝐭𝐡𝐞 𝐩𝐚𝐭𝐞𝐧𝐭 𝐜𝐥𝐢𝐟𝐟 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚 𝐢𝐦𝐩𝐚𝐜𝐭 𝐫𝐞𝐯𝐞𝐧𝐮𝐞?

The patent cliff is approaching fast, with drugs representing $350 billion in annual worldwide revenues set to lose their exclusivity by 2030. The top 20 pharma companies account for 80% of this revenue loss.

𝐇𝐨𝐰 𝐉𝐨𝐡𝐧𝐬𝐨𝐧 & 𝐉𝐨𝐡𝐧𝐬𝐨𝐧 𝐞𝐚𝐫𝐧𝐞𝐝 𝐚𝐧𝐝 𝐬𝐩𝐞𝐧𝐭 𝐦𝐨𝐧𝐞𝐲 𝐢𝐧 2024?

Pharmaceutical companies have started releasing their financial statements for 2024. One of the first to do so is Johnson & Johnson, which announced its results earlier this week.

Here is the graphic of their FY24 Income Statement